In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type 2 selected

Type

Guidance programme 6 selected

Guidance programme

Showing 1 to 9 of 9

TitleConsultationTypeConsultation end date
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]Draft guidanceTechnology appraisal guidance
Tarlatamab for treating small-cell lung cancer that has progressed after platinum-based chemotherapy ID6617Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphomaReview proposal consultationTechnology appraisal guidance
Guidance on the use of electroconvulsive therapyReview proposal consultationTechnology appraisal guidance
Pharmalgen for the treatment of bee and wasp venom allergyReview proposal consultationTechnology appraisal guidance
Pharmalgen for the treatment of bee and wasp venom allergyReview proposal consultationTechnology appraisal guidance
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsHighly specialised technology
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]Final draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All